The recent SHARP trial clearly demonstrated that a reduction in low-density lipoprotein ( LDL ) cholesterol with a daily regimen of simvastatin plus ezetimibe safely reduced the incidence of major atherosclerotic events in patients with chronic kidney disease ( CKD ) .